BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lonardo A, Arab JP, Arrese M. Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. Adv Ther 2021;38:2130-58. [PMID: 33829368 DOI: 10.1007/s12325-021-01690-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 19.0] [Reference Citation Analysis]
Number Citing Articles
1 Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism 2021;126:154925. [PMID: 34740573 DOI: 10.1016/j.metabol.2021.154925] [Reference Citation Analysis]
2 Pelechá M, Villanueva-bádenas E, Timor-lópez E, Donato MT, Tolosa L. Cell Models and Omics Techniques for the Study of Nonalcoholic Fatty Liver Disease: Focusing on Stem Cell-Derived Cell Models. Antioxidants 2022;11:86. [DOI: 10.3390/antiox11010086] [Reference Citation Analysis]
3 Flessa C, Kyrou I, Nasiri‐ansari N, Kaltsas G, Kassi E, Randeva HS. Endoplasmic reticulum stress in nonalcoholic (metabolic associated) fatty liver disease (NAFLD/MAFLD). J of Cellular Biochemistry. [DOI: 10.1002/jcb.30247] [Reference Citation Analysis]
4 Tong XF, Wang QY, Zhao XY, Sun YM, Wu XN, Yang LL, Lu ZZ, Ou XJ, Jia JD, You H. Histological assessment based on liver biopsy: the value and challenges in NASH drug development. Acta Pharmacol Sin 2022;43:1200-9. [PMID: 35165400 DOI: 10.1038/s41401-022-00874-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Tang R, Li R, Li H, Ma XL, Du P, Yu XY, Ren L, Wang LL, Zheng WS. Design of Hepatic Targeted Drug Delivery Systems for Natural Products: Insights into Nomenclature Revision of Nonalcoholic Fatty Liver Disease. ACS Nano 2021. [PMID: 34705426 DOI: 10.1021/acsnano.1c02158] [Reference Citation Analysis]
6 Lonardo A. Metabolomic signature: one step forward in the process of obtaining NAFLD patients' metabolic identity card. Am J Clin Nutr 2022;115:603-5. [PMID: 35134121 DOI: 10.1093/ajcn/nqab399] [Reference Citation Analysis]
7 Pellicori P, Vaduganathan M, Ferreira JP, Zannad F, Sanyal AJ. Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: Implications for future trial design. Diabetes Metab 2021;:101281. [PMID: 34543735 DOI: 10.1016/j.diabet.2021.101281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Seo JY, Bae JH, Kwak MS, Yang JI, Chung SJ, Yim JY, Lim SH, Chung GE. The Risk of Colorectal Adenoma in Nonalcoholic or Metabolic-Associated Fatty Liver Disease. Biomedicines 2021;9:1401. [PMID: 34680518 DOI: 10.3390/biomedicines9101401] [Reference Citation Analysis]
9 Lonardo A. Back to the future: From the history of NAFLD to MAFLD to heterogeneity of disease. Clinical and Translational Dis 2021;1. [DOI: 10.1002/ctd2.9] [Reference Citation Analysis]
10 Arrese M, Arab JP, Barrera F, Kaufmann B, Valenti L, Feldstein AE. Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Semin Liver Dis 2021. [PMID: 34233370 DOI: 10.1055/s-0041-1730927] [Reference Citation Analysis]
11 Von-hafe M, Borges-canha M, Vale C, Leite AR, Sérgio Neves J, Carvalho D, Leite-moreira A. Nonalcoholic Fatty Liver Disease and Endocrine Axes—A Scoping Review. Metabolites 2022;12:298. [DOI: 10.3390/metabo12040298] [Reference Citation Analysis]
12 Lonardo A. Separating the apples from the oranges: from NAFLD heterogeneity to personalized medicine. Exploration of Medicine. [DOI: 10.37349/emed.2021.00061] [Reference Citation Analysis]
13 Gluvic Z, Tomasevic R, Bojovic K, Obradovic M, Isenovic ER. Non-alcoholic fatty liver disease: a multidisciplinary clinical practice approach—the institutional adaptation to existing Clinical Practice Guidelines. Emergency and Critical Care Medicine 2022;2:12-22. [DOI: 10.1097/ec9.0000000000000016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Milic J, Barbieri S, Gozzi L, Brigo A, Beghé B, Verduri A, Bacca E, Iadisernia V, Cuomo G, Dolci G, Yaacoub D, Aprile E, Belli M, Venuta M, Meschiari M, Sebastiani G, Clini E, Mussini C, Lonardo A, Guaraldi G, Raggi P. Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome. Open Forum Infect Dis 2022;9:ofac003. [PMID: 35146047 DOI: 10.1093/ofid/ofac003] [Reference Citation Analysis]
15 Arab JP, Díaz LA, Dirchwolf M, Mark H, Lazarus JV, Vaughan E, Méndez-Sánchez N, de Oliveira CP, Gadano A, Arrese M. NAFLD: Challenges and opportunities to address the public health challenge in Latin America. Ann Hepatol 2021;24:100359. [PMID: 34004366 DOI: 10.1016/j.aohep.2021.100359] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Tzanaki I, Agouridis AP, Kostapanos MS. Is there a role of lipid-lowering therapies in the management of fatty liver disease? World J Hepatol 2022; 14(1): 119-139 [DOI: 10.4254/wjh.v14.i1.119] [Reference Citation Analysis]
17 Lonardo A. Separating the apples from the oranges: from NAFLD heterogeneity to personalized medicine. Exploration of Medicine. [DOI: 10.37349/emed.2021.00061] [Reference Citation Analysis]